Cite
Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
MLA
Igarashi, Kentaro, et al. “Recombinant Methioninase in Combination with Doxorubicin (DOX) Overcomes First-Line DOX Resistance in a Patient-Derived Orthotopic Xenograft Nude-Mouse Model of Undifferentiated Spindle-Cell Sarcoma.” Cancer Letters, Mar. 2018, pp. 168–73. EBSCOhost, https://doi.org/10.1016/j.canlet.2017.12.028.
APA
Igarashi, K., Kawaguchi, K., Li, S., Han, Q., Tan, Y., Murakami, T., Kiyuna, T., Miyake, K., Miyake, M., Singh, A. S., Eckardt, M. A., Nelson, S. D., Russell, T. A., Dry, S. M., Li, Y., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., & Tsuchiya, H. (2018). Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. Cancer Letters, 168–173. https://doi.org/10.1016/j.canlet.2017.12.028
Chicago
Igarashi, Kentaro, Kei Kawaguchi, Shukuan Li, Qinghong Han, Yuying Tan, Takashi Murakami, Tasuku Kiyuna, et al. 2018. “Recombinant Methioninase in Combination with Doxorubicin (DOX) Overcomes First-Line DOX Resistance in a Patient-Derived Orthotopic Xenograft Nude-Mouse Model of Undifferentiated Spindle-Cell Sarcoma.” Cancer Letters, March, 168–73. doi:10.1016/j.canlet.2017.12.028.